

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): December 2, 2019**

---

**Proteostasis Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-37695**  
(Commission  
File Number)

**20-8436652**  
(I.R.S. Employer  
Identification No.)

**80 Guest Street, Suite 500**  
**Boston, MA**  
(Address of principal executive offices)

**02135**  
(Zip Code)

**Registrant's telephone number, including area code (617) 225-0096**

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value \$0.001 per share	PTI	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

---

**Item 8.01. Other Events.**

On December 2, 2019, Proteostasis Therapeutics, Inc. (the “Company”) issued a press release announcing that it received a letter dated November 27, 2019 from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that it has regained compliance with the requirement of The Nasdaq Global Market to maintain a minimum bid price of \$1.00 per share, as set forth in Nasdaq Listing Rule 5450 (a)(1), and that the matter is now closed. A copy of this press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

<u>Exhibit No.</u>	<u>Exhibit Name</u>
99.1	<a href="#">Press Release issued by the Company on December 2, 2019</a>

---

**EXHIBIT INDEX**

<u>Exhibit No.</u>	<u>Exhibit Name</u>
99.1	<a href="#">Press Release issued by the Company on December 2, 2019.</a>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 2, 2019

**PROTEOSTASIS THERAPEUTICS, INC.**

By: /s/ Meenu Chhabra

Meenu Chhabra

President and Chief Executive Officer



### **Proteostasis Therapeutics Regains Compliance with Nasdaq Listing Standards**

**BOSTON, Mass. – December 2, 2019** – Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced that it received a letter dated November 27, 2019 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with the requirement of The Nasdaq Global Market to maintain a minimum bid price of \$1.00 per share. The letter noted that as of November 26, 2019, the Company evidenced a closing bid price of its common stock in excess of the \$1.00 minimum requirement for at least ten consecutive trading days. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5450(a)(1) and Nasdaq considers the matter closed.

#### **About Proteostasis Therapeutics, Inc.**

Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis and other diseases caused by dysfunctional protein processing. Headquartered in Boston, MA, the Proteostasis Therapeutics team focuses on identifying therapies that restore protein function. For more information, visit [www.proteostasis.com](http://www.proteostasis.com).

#### **Safe Harbor**

To the extent that statements in this release are not historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “aim,” “may,” “will,” “expect,” “anticipate,” “estimate,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements made in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we, therefore cannot assure you that our plans, intentions, expectations or strategies will be attained or achieved. Such risks and uncertainties include, without limitation, those set forth in our Annual Report on Form 10-K for the year ended December 31, 2018, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 and our other SEC filings. We assume no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

#### **CONTACTS:**

##### **Investors:**

David Pitts / Claudia Styslinger

Argot Partners

212.600.1902

[david@argotpartners.com](mailto:david@argotpartners.com) / [claudia@argotpartners.com](mailto:claudia@argotpartners.com)

##### **Media:**

David Rosen

Argot Partners

212.600.1902

[david.rosen@argotpartners.com](mailto:david.rosen@argotpartners.com)